T1	Participants 102 221	patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both
T2	Participants 305 318	heart failure
T3	Participants 577 706	patients with systolic dysfunction and heart failure receiving therapeutic inhibition of the renin-angiotensin-aldosterone system
T4	Participants 1496 1558	Patients who died or experienced heart failure hospitalization
